The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | CAR-T cell approaches in CLL: current progress & future directions
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, shares some insights into the efficacy of CAR-T cell therapy in patients with chronic lymphocytic leukemia (CLL), commenting on the Phase I/II TRANSCEND-CLL-004 trial (NCT03331198). Prof. Ghia also highlights areas for further study to improve outcomes with the use of CAR-T cell approaches to treat CLL in the future. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
